Amgen’s UPLIZNA Becomes First FDA-Approved Treatment for IgG4-Related Disease
Amgen announced that the FDA has approved UPLIZNA (inebilizumab-cdon) as the first and only treatment for adults with Immunoglobulin G4-related disease (IgG4-RD), a rare and chronic immune-mediated inflammatory condition that can affect multiple organ systems. The approval marks a significant milestone for patients living with IgG4-RD, which often mimics other diseases and may result in fibrosis or permanent organ damage if left untreated. UPLIZNA had previously received Breakthrough Therapy Designation for this indication, highlighting the urgent need for effective therapies.
“The FD...
